Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNTH-2404
- Development stage
- Preclinical
- Lead developer
- Lantheus
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Unknown
01
Overview
LNTH-2404 is a preclinical-stage, targeted radiotherapeutic based on a nanobody platform. It is designed to deliver alpha-emitting ionizing radiation (actinium-225 radionuclide) selectively to tumor cells that overexpress Trophoblast cell surface antigen 2 (TROP2), a clinically validated cancer antigen prevalent in many solid tumors. LNTH-2404 is being developed for the treatment of TROP2-expressing solid tumors and is currently not approved for any indication. The product originated from Radiopharm Theranostics (where it was also known as RAD-206) and is now under development by Lantheus Holdings following an in-license acquisition[2][3][5][9].
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on LNTH-2404.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNTH-2404.